88 results about "Tropomyosin" patented technology

The invention relates to the field of biochips, and particularly relates to a surface plasma resonance immunosense chip as well as a preparation method and application thereof. The surface plasma resonance immunosense chip is prepared by the following steps: fixing a shrimp tropomyosin, shrimp tropomyosin monoclonal antibody ascites or a shrimp tropomyosin monoclonal antibody on a solid phase carrier as a bioprobe; generating surface plasma resonance response by utilizing a gold membrane; modifying sulfydryl on the surface of the gold membrane by utilizing a self-assembly monomolecular layer technique; and fixing the probe on the biochip after the chip is activated. The biochip can be applied to detection of the shrimp tropomyosin monoclonal antibody or the shrimp tropomyosin monoclonal antibody ascites, and detection of the allergen (shrimp tropomyosin), has the advantage of simplicity and convenience in operation, rapidity, high flexibility, no need of being labeled, low cost, simple device, no pollution to the environment and the like, and is hopeful to realize the field real-time detection of a great amount of samples.

The invention relates to a colloidal gold immunochromatographic test strip for detecting shrimp allergen and a preparation method thereof, belonging to the technical field of immunoassay. The invention discloses the assembled test strip which takes a combination of shrimp allergen-tropomyosin cluster specific antibody and color-developing substance colloidal gold as a detection reagent, the test strip is used for detecting the shrimp allergen in a food, and the test strip has low cost, fastness and portability. The applied antibody is an extracted and purified polyclonal antibody from a New Zealand rabbit with tropomyosin immune health. Due to the adoption of the polyclonal antibody, the test strip has low cost, good stability and good repeatability, and can be used in the detection of different samples.

The present invention relates to a tumor marker for diagnosis of ovarian cancer, which is selected from the group consisting of alectin-1, cathepsin B, MHC class I antigen, heat shock protein (HSP) 27, ubiquitin carboxy-termal esterase L1, cellular retinol-binding protein (CRBP), transthyretin, SH3 binding glutamate-rich protein, tubulin-specific chaperone A, RNA binding protein regulatory subunit, γ-actin, tropomyosin and calcium / calmodulin-stimulated cyclic nucleotide phosphatase. The ovarian cancer is diagnosed effectively and efficiently based on detecting the expression levels of the tumor markers in the invention from the ovarian tissue sample of an individual to be diagnosed.

The invention relates to an idiopathic pulmonary fibrosis urine protein marker, and application of the same to diagnosis and prognosis. Specifically, the invention relates to application of a urine protein marker obtained by using an idiopathic pulmonary fibrosis model and mass spectrometry to early-stage diagnosis, pathogenesis monitoring and curative effect assessment of human pulmonary fibrosis. The urine protein marker comprises collagen alpha-1(I) chain, vimentin, protein RUFY3, keratin type-II skeleton 8, a sodium-hydrogen exchange regulation factor NHE-RF2, a threonine synthase sample 2, zinc-actin binding repeat protein 2, low-density lipoprotein receptor-associated protein 4, alpha-11 of a guanine nucleotide binding protein subunit, an alpha-1 chain of tropomyosin, mitochondrial stress-70 protein, NSFL1 cofactor P47, ubiquitin carboxyl-terminal hydrolase isozyme L1, etc.

The invention discloses a method for detecting tropomyosin by means of a homologous epitope peptide antibody. An immune analysis mode of developing detection methods one by one according to single allergens is broken through, and according to allergens of aquatic products such as shrimps and crabs, a race-specific epitope peptide antibody with broad-spectrum recognition capability is researched and prepared, a novel aquatic product allergen detection method is developed, and high-throughput rapid detection of the allergens in the aquatic products is achieved.

The invention discloses a preparation method of shrimp tropomyosin allergen primary standard substance, and belongs to the technical field of biology. The invention relates to a method used for high-efficient stable extraction, separation and purification of main allergen protein tropomyosin from shrimp meat. According to the method, a plurality of technologies, such as immersing extraction, thermoprecipitation, and affinity chromatography are combined for purification of the tropomyosin, the tropomyosin with high allergen performance is extracted from shrimp meat, and original activity is maintained. The tropomyosin obtained via the method is helpful for researches on shrimp allergy, and can be used for immunization technology to detect shrimp allergen in foods.

The invention discloses bovine lactoferricin-human lysozyme fused protein. The bovine lactoferricin-human lysozyme fused protein is characterized by comprising porcine myofibrillar protein antioxidative peptide, bovine lactoferricin, hen egg white protein antioxidative peptide, porcine muscle myosin antioxidative peptide, flexible peptide and human lysozyme which are connected in series. Through anionic antioxidative peptide derived from fusion expression animals, the positive charge of antimicrobial peptide is neutralized, and inhibition to host bacteria by antimicrobial peptide is reduced; antioxidative peptide is beneficial to the improvement of storage stability of the antimicrobial peptide, the antibacterial activity to escherichia coli (ATCC 25922) by the fused protein is only reduced by 7.7 percent after the fused protein is laid for 20d at 4 DEG C, and the loss of activity to the escherichia coli (ATCC 25922) by the fused protein is only reduced by 15.4 after the fused proteinis laid for 30d.

The present invention discloses a Chinese medicine chaenomeles fruit peach kernel capsule and its preparation method. It is made up by using the Chinese medicinal materials of chaenomeles fruit, peach kernel, cinnamon bark, coix seed and black-striped snake through a certain preparation process. Said capsule has the functions of expelling wind, removing dampness, clearing and activating the channels and collaterals, and can be mainly used for curing the diseases of rheumatic arthritis, rheumatoid arthritis, osteoarthropathy, cervicodynia, lumbago and scelalgia, etc. Besides, said invention also provides the concrete steps of its preparation method.

The present invention relates to a tumor marker for diagnosis of ovarian cancer, which is selected from the group consisting of galectin-1, cathepsin B, MHC class I antigen, heat shock protein (HSP) 27, ubiquitin carboxy-termal esterase L1, plasma retinol-binding protein (PRBP), transthyretin, SH3 binding glutamate-rich protein, tubulin-specific chaperone A, RNA binding protein regulatory subunit, γ-actin, tropomyosin and calcium / calmodulin-stimulated cyclic nucleotide phosphatase. The ovarian cancer is diagnosed effectively and efficiently based on detecting the expression levels of the tumor markers in the invention from the ovarian tissue sample of an individual to be diagnosed.

The invention discloses an improved protein mMet el for relieving tropomyosin sensitization response of prawns as well as a preparation method and application of the improved protein. The improved protein mMet el has an amino acid sequence shown as SEQ ID NO:1. The preparation method comprises the following steps: (1) contrasting metapenaeus tropomyosin mMet el antigen-specific epitope amino acid sequences and tropomyosin sequences of four marine fishes, performing amino acid sequence analysis, and redesigning antigen epitope amino acid residue sequences so as to obtain the amino acid sequence of the improved protein mMet el; (2) performing reverse transcription and translation so as to obtain cDNA; (3) treating and combining the obtained cDNA and vector plasmids through restriction enzymes so as to obtain a recombinant plasmid vector; (4) introducing the recombinant plasmid vector into host bacteria, and expressing the improved protein mMet el; (5) purifying, thereby obtaining a standard substance of the improved protein mMet el. The improved protein disclosed by the invention has the characteristics of high yield, stable production and low cost.

The invention discloses a purifying method of shrimp tropomyosin and particularly discloses a purifying method which is high in purity and beneficial to large-scale production. The purifying method comprises the following steps: dissolving a shrimp tropomyosin crude product into equilibration buffer with a pH value of 3.2-3.6 to obtain a sample liquid; adding the sample liquid into an anionic chromatography column, eluting by use of equilibration buffer with the pH value of 3.2-3.6, collecting the liquid corresponding to a column penetrating peak; regulating the pH value of the liquid corresponding to the column penetrating peak to 5.8-6.0, adding the liquid into a cationic hromatography column, eluting by use of equilibration buffer with the pH value of 5.8-6.0, collecting the liquid corresponding to the column penetrating peak, performing dialysis and desalination, and drying to obtain the high-purity shrimp tropomyosin. According to the purifying method disclosed by the invention, a target protein exists in the column penetrating column by combining anion exchange chromatography with cation exchange chromatography, so that the activity of the protein can be kept very well, and the purity of the obtained protein is high; by virtue of two-step ion-exchange column chromatography, the purifying method is great in treatment capacity, simple to operate and beneficial to large-scale production.

The present invention provides methods for detecting, analyzing, and identifying biomolecules used to identifying patient with dengue-like symptom who are at risk of DHF. The inventive method comprises detecting in a sample from a subject dengue infected patient one or more biomarkers selected from the group consisting of IL-10, fibrinogen, C4A, immunoglobulin, tropomyosin, and three isoforms of albumin, and which are used in a predictive MARS model to detect patients with risk of developing DHF.

The invention belongs to the technical field of processing of aquatic products and discloses a high-yield low-pollution discharge acid soluble method for extracting fish protein and minced fillet thereof. The method has high yield and low wastewater emission and is particularly suitable for extracting tilapia proteins. The method comprises the following steps: (1) mixing the pretreated aquatic raw materials and water, homogenizing at a high speed, and forming fish homogenate; (2) regulating the pH value of the fish homogenate to be acidic; (3) performing ultrasonic treatment on the acidic fish homogenate, and separating the impurities from the protein solution; and (4) regulating the pH value of the protein solution to an isoelectric point so as to precipitate the proteins, separating, thereby obtaining the fish proteins. According to the method disclosed by the invention, the fish meat or fishbone and fish skin leftovers for producing the minced fillet can serve as raw materials, high yield can be realized by adopting gentle acidic conditions, the usage amount of chemical reagents is reduced, the rate of actin and tropomyosin in the fish proteins is high, the gel deformation degree is high, and the obtained minced fillet is good in taste.

The invention discloses hybridoma cells of shrimp tropomyosin monoclonal antibodies and application thereof, and belongs to the field of food safety immunodetection. Hybridoma cell strains FB12-1 of the shrimp tropomyosin monoclonal antibodies are preserved in China Committee for Culture Collection Center for general microbiology on September 5th, 2017, the preservation number is CGMCCNo.14690, and the preservation address is Institute of Microbiology, the Chinese Academy of Sciences, No.3, Courtyard No.1, West Beichen Road, Chaoyang District, Beijing City. Antibodies 7H6 secreted by the cellstrains FB12-1 are coated with antibodies; HRP (Horse Radish Peroxidase) marked by the antibodies 7H6 are enzyme labelled antibodies (7H6-HRP). By using shrimp tropomyosin as a standard product, a double-antibody sandwich enzyme-linked immunodetection method for detecting the shrimp tropomyosin is built, and hybridoma cells are applied to detection of food allergens and have practical applicationvalues.

The invention relates to the technical field of separation. The invention discloses a preparation method of an agarose boric acid affinity material suitable for fish tropomyosin purification. The novel agarose boric acid affinity material is prepared by taking 3,5-difluoro-4-formylphenylboronic acid as a functional monomer, tri (2-aminoethyl)amine as a multi-branched ligand and agarose microspheres as a matrix material, and is used for separation and purification of fish tropomyosin for the first time, wherein optimal use conditions are determined by using different fish samples. Results showthat when the agarose concentration is 3%, the pH value of the loading equilibrium liquid is 7.4 and the concentration of the HAc eluent is 100 mM, the purity of the obtained tropomyosin reaches 90% or above, and the column capacity reaches 1.85 mg / mL or above. Compared with a traditional method, the method can remarkably shorten the purification time (shortened from several days to 3-4 hours), noorganic solvent is used, and the product purity is equivalent to that of the traditional method.

Disclosed herein, are methods of treating a neuroendocrine tumor (NET) in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that inhibits a tropomyosin receptor kinase (Trk) protein, wherein the NET is associated with a Trk protein that has undergone a genetic translocation or is an NTRK gene fusion protein. Also disclosed herein are methods of treating a neuroendocrine tumor (NET) in an individual in need thereof, comprising: (a) obtaining a sample of NET genetic material from the individual; (b) determining whether the NET tumor comprises a NTRK translocation or gene fusion; and (c) administering to the individual a therapeutically effective amount of an agent that inhibits a tropomyosin receptor kinase (Trk) protein.

The invention discloses a method for rapidly detecting shrimp tropomyosin through capillary electrophoresis. The method comprises the following steps that 1, holoprotein in shrimp muscle is extracted, dissolved in an equilibration buffer with the pH of 7-8, added into an anion exchange chromatographic column and eluted through an elution solution, and a solution corresponding to a penetrating peak is collected as a sample; 2, the obtained sample is subjected to capillary zone electrophoresis to obtain an electrophoretogram, the peak area in the electrophoretogram is substituted into a standard curvilinear regression equation to calculate the concentration of the tropomyosin in the obtained sample. According to the method for rapidly detecting allergen-shrimp tropomyosin of aquatic products through capillary electrophoresis, holoprotein in shrimp muscle is extracted, added into the anion exchange chromatographic column and eluted through the elution solution, the solution corresponding to the penetrating peak is collected and added into a capillary electrophoresis apparatus, and qualitative and quantitative detection is carried out on the shrimp tropomyosin in the sample solution through capillary zone electrophoresis.

The present invention relates to a tumor marker for diagnosis of ovarian cancer, which is selected from the group consisting of galectin-1, cathepsin B, MHC class I antigen, heat shock protein (HSP) 27, ubiquitin carboxy-termal esterase L1, plasma retinol-binding protein (PRBP), transthyretin, SH3 binding glutamate-rich protein, tubulin-specific chaperone A, RNA binding protein regulatory subunit, γ-actin, tropomyosin and calcium / calmodulin-stimulated cyclic nucleotide phosphatase. The ovarian cancer is diagnosed effectively and efficiently based on detecting the expression levels of the tumor markers in the invention from the ovarian tissue sample of an individual to be diagnosed.

The invention belongs to the field of detection, particularly relates to tropomyosin in crustacean aquatic products such as shrimps, crabs and other molluscs, and discloses a sample pretreating methodsuitable for quickly detecting tropomyosin in the crustacean aquatic products on site and a detection reagent box thereof. A test strip comprises a bottom plate, a sample pad, a binding pad, a nitrocellulose membrane and a water absorbing pad; the sample pad, the binding pad, the nitrocellulose membrane and the water absorbing pad are sequentially pasted to the upper surface of the bottom plate in a staggered mode from one end to the other end; the binding pad is a binding pad marked by magnetic beads modified by anti-tropomyosin specificity rat monoclonal antibodies; the nitrocellulose membrane is a nitrocellulose membrane precoated with a detection line for Tm detection antigen and a control line for goat anti-mouse IgG. By means of the sample pretreating method suitable for quickly detecting tropomyosin in the crustacean aquatic products on site and the quick detection reagent box thereof, the content of tropomyosin in a detected sample can reach 5 microgram / mL within a visual range.

The invention provides epitope peptide of a tropomyosin antigen, and an application of the epitope peptide. The epitope peptide of the tropomyosin antigen comprises: (a) an amino acid sequence selected from SEQ ID No. 1-5; or (b) an amino acid sequence having at least 80% identity with the amino acid sequence selected from SEQ ID No. 1-5, can be used for developing tropomyosin with reduced sensitization, or used for detecting whether an antibody of the tropomyosin antigen exists in a sample, or used for detecting whether a subject is allergic to the tropomyosin antigen, and has good application prospects.

The present invention provides isolated peptides and nucleic acids encoding the isolated peptides that can modify a subject's immune response to tropomyosin. The isolated peptides correspond to peptide epitope mimics that are based on an invertebrate tropomyosin allergen, e.g., the shrimp tropomyosin Met e 1. Also provided are compositions and methods of use thereof to reduce, minimize or eliminate an allergic response to arthropods and / or shellfish.

The invention discloses a high flux screening method for screening a tropomyosin-related kinase B inhibitor, which comprises the following steps: 1)establishment and optimization of a screening model of the tropomyosin-related kinase B inhibitor: performing kinases concentration, incubation time, substrate concentration and ATP concentration experiments; 2)model reliability verification with positive drug: selecting kinases with appropriate concentration, ATP Km and substrate Km, respectively adding 2muml kinases and the substrate in each pore, adding 4muml positive drug in each pore according to concentration gradient, adding 2muml ATP for reacting, incubating at room temperature according to optimization time, adding 10muml stopping solution in each pore for stopping the reaction, incubating for 1 hour at room temperature and then detecting, analyzing data to obtain the positive drug IC50; and 3)verification of the high flux screen model: operating according to the above steps, using a Biomek NXP automation sampling apparatus and a Multidrop automatic liquid separator for feeding samples, and then calculating Z factors. The method has the advantages of simpleness and rapidity, high sensitivity, stable and reliable result and good reappearance, and can be used for high flux screening.

The invention discloses a carbamate compound, a pharmaceutical composition and application of the carbamate compound and belongs to the technical field of pharmaceutical compound synthesis. The carbamate compound is a compound of a general formula I or general formula II shown in the description, or a pharmaceutically acceptable salt of the compound. The carbamate compound disclosed by the invention has remarkable effects in preventing and / or treating TRK (tropomyosin-related kinase) mediated diseases with pathological characteristics.

The present invention provides an ex vivo method for aiding the diagnosis of Alzheimer's disease in a patient, the method comprising the steps of determining the level of expression of at least four platelet proteins in a platelet sample from the patient selected from monoamine oxidase-B, coagulation factor Xllla, total tropomyosin (a and 13), WD-repeat protein 1 and apolipoprotein E4; and comparing the result of (i) to a control value, wherein a result higher than the control value is indicative of Alzheimer's disease. Preferably, the method of the invention further comprises determining the level of expression of wild-type GSTO-1 or mutant GSTO-1.

The invention provides application of bacteroides thetaotaomicron to preparation of a food or medicine for preventing, relieving or treating allergy to tropomyosin in foods; the bacteroides thetaiotaomicron is collected in China Center for Type Culture Collection on April 30, 2020, and the collection number is CCTCC M 2020105. The bacteroides thetaotaomicron can regulate the imbalance of Th1 / Th2 and Th17 / Treg cell subsets, so that the allergic reaction caused by the tropomyosin in the foods can be relieved; immune diseases including food allergy, bronchial asthma and the like are relieved; andthe bacteroides thetaotaomicron has high pertinence, high economic benefits, and few side effects, and the raw materials are green, environment-friendly and pollution-free.

Disclosed herein, are methods of treating a neuroendocrine tumor (NET) in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that inhibits a tropomyosin receptor kinase (Trk) protein, wherein the NET is associated with a Trk protein that has undergone a genetic translocation or is an NTRK gene fusion protein. Also disclosed herein are methods of treating a neuroendocrine tumor (NET) in an individual in need thereof, comprising: (a) obtaining a sample of NET genetic material from the individual; (b) determining whether the NET tumor comprises a NTRK translocation or gene fusion; and (c) administering to the individual a therapeutically effective amount of an agent that inhibits a tropomyosin receptor kinase (Trk) protein.

The invention provides a kit for detecting an antigen myosin 1-IgG antibody. The kit consists of an antigen protein Tropomyosin 1 (tropomyosin 1), a solid phase carrier, a standard substance, a positive quality control substance, a negative quality control substance, a labeled antibody, a substrate developing solution, an antibody diluent, an antigen diluent, a sample dilution buffer solution, a washing solution, a stop solution and the like. According to the invention, a target antigen Tropomyosin 1 corresponding to an anti-Tropomyosin 1-IgG antibody is utilized, and IgG of human anti-tag peptide is used as a standard substance for quantitative detection, so that the anti-Tropomyosin 1-IgG antibody detection is carried out on an antigen-antibody compound formed in serum. The kit disclosed by the invention is simple and convenient to operate, very good in reagent stability and convenient to store, and fills the blank of identifying biomarkers of immune nephrotic syndrome patients at home and abroad.

A method for accurate and precise measurement of target proteins such as food allergen proteins in the specific foods is provided. The method is a method for immunological measurement of a food allergen protein in a processed food using an antibody against the food allergen protein, comprising adding animal tropomyosin to an assay solution upon measurement.

The present invention provides methods for detecting, analyzing, and identifying biomolecules used to identifying patient with dengue-like symptom who are at risk of DHF. The inventive method comprises detecting in a sample from a subject dengue infected patient one or more biomarkers selected from the group consisting of IL-10, fibrinogen, C4A, immunoglobulin, tropomyosin, and three isoforms of albumin, and which are used in a predictive MARS model to detect patients with risk of developing DHF.